Trails Edge Capital Partners, LP
Reported holdings as of Q2 2026, from 3 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| LB PHARMACEUTICALS INC | LBRX | $49.4M | 1,523,022 | +0.39pp | 3q | +15.4%+$6.6M | |
| NURIX THERAPEUTICS INC | NRIX | $38.2M | 1,573,220 | -0.13pp | 3q | -9.8%-$4.1M | |
| IMMUNOCORE HLDGS PLC | IMCR | $33.8M | 1,063,234 | +0.64pp | 3q | +55.8%+$12.1M | |
| FIRST TRACKS BIOTHERAPEUTICS | TRAX | $30.5M | 1,514,000 | - | new | NEW | |
| 4D MOLECULAR THERAPEUTICS IN | FDMT | $29.6M | 2,227,917 | +1.93pp | 2q | +71.0%+$12.3M | |
| BIOMARIN PHARMACEUTICAL INC | BMRN | $29.3M | 512,000 | - | new | NEW | |
| DESIGN THERAPEUTICS INC | DSGN | $29.0M | 2,001,282 | +2.52pp | 2q | +134.9%+$16.6M | |
| XENON PHARMACEUTICALS INC | XENE | $26.6M | 440,000 | -4.31pp | 3q | HELD | |
| MIRUM PHARMACEUTICALS INC | MIRM | $26.1M | 223,312 | -2.90pp | 3q | -33.0%-$12.9M | |
| INSMED INC | INSM | $24.6M | 230,331 | - | new | NEW | |
| CYTOKINETICS INC | CYTK | $24.5M | 288,089 | -0.63pp | 2q | -4.0%-$1.0M | |
| SYNDAX PHARMACEUTICALS INC | SNDX | $24.3M | 1,110,000 | +0.10pp | 2q | +58.2%+$8.9M | |
| NEUROGENE INC | NGNE | $22.5M | 714,885 | -0.05pp | 3q | -8.7%-$2.1M | |
| KAILERA THERAPEUTICS INC | KLRA | $21.7M | 984,786 | - | new | NEW | |
| REVOLUTION MEDICINES INC | RVMD | $21.7M | 115,750 | -2.02pp | 2q | -52.8%-$24.2M | |
| INHIBIKASE THERAPEUTICS INC | IKT | $18.4M | 9,051,318 | -0.18pp | 3q | +12.3%+$2.0M | |
| INCYTE CORP | INCY | $17.6M | 155,000 | - | new | NEW | |
| AVALO THERAPEUTICS INC | AVTX | $16.5M | 891,881 | - | new | NEW | |
| MOONLAKE IMMUNOTHERAPEUTICS | MLTX | $14.6M | 750,000 | - | new | NEW | |
| FAETH THERAPEUTICS INC | FTH | $12.9M | 515,335 | +1.14pp | 2q | +312.3%+$9.8M | |
| X4 PHARMACEUTICALS INC | XFOR | $12.0M | 2,571,478 | -0.53pp | 3q | HELD | |
| OPUS GENETICS INC | IRD | $11.3M | 2,743,658 | +1.27pp | 2q | +448.7%+$9.2M | |
| SOL-GEL TECHNOLOGIES LTD | SLGL | $10.3M | 139,445 | +0.09pp | 2q | +63.1%+$4.0M | |
| AURA BIOSCIENCES INC | AURA | $10.2M | 1,443,333 | - | new | NEW | |
| CENTURY THERAPEUTICS INC | IPSC | $10.1M | 4,134,969 | +0.34pp | 2q | +68.8%+$4.1M | |
| INVENTIVA SA | IVA | $10.0M | 2,657,997 | -1.78pp | 3q | HELD | |
| CAMP4 THERAPEUTICS CORP | CAMP | $8.4M | 1,932,937 | -0.62pp | 3q | HELD | |
| ALTIMMUNE INC | ALT | $8.1M | 2,660,000 | - | new | NEW | |
| MINERVA NEUROSCIENCES INC | NERV | $7.9M | 1,419,000 | -0.71pp | 2q | HELD | |
| PROMIS NEUROSCIENCES INC | PMN | $7.3M | 557,103 | -0.46pp | 2q | HELD | |
| ONKURE THERAPEUTICS INC | OKUR | $6.6M | 1,438,456 | - | new | NEW | |
| FORTE BIOSCIENCES INC | FBRX | $5.8M | 273,181 | - | new | NEW | |
| RESEARCH ALLIANCE CORP III | RACC | $5.3M | 500,000 | - | new | NEW | |
| VTV THERAPEUTICS INC | VTVT | $3.2M | 85,192 | -0.76pp | 3q | -39.0%-$2.0M | |
| IMAGENEBIO INC | IMA | $1.7M | 282,004 | - | new | NEW |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $572.4M | 90.9% |
| Not classified | $57.5M | 9.1% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $629.9M | 35 | 13 | 10 | 6 | 4 | 50.3% | 45 |
| Q1 2026 | $436.5M | 26 | 12 | 4 | 5 | 9 | 65.5% | 45 |
| Q4 2025 | $404.7M | 23 | 0 | 0 | 0 | 0 | 68.5% | 48 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.